about
A novel laser vaccine adjuvant increases the motility of antigen presenting cellsAS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in FinlandNeurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden.Laser vaccine adjuvant for cutaneous immunization.Immune enhancement by novel vaccine adjuvants in autoimmune-prone NZB/W F1 mice: relative efficacy and safety.The impact of influenza vaccinations on the adverse effects and hospitalization rate in the elderly: a national based study in an Asian country.Pollen lipidomics: lipid profiling exposes a notable diversity in 22 allergenic pollen and potential biomarkers of the allergic immune responseToxicology of autoimmune diseases.Polyreactivity and autoreactivity among HIV-1 antibodies.Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane)Phytol-based novel adjuvants in vaccine formulation: 1. assessment of safety and efficacy during stimulation of humoral and cell-mediated immune responsesPeptide amphiphile micelles self-adjuvant group A streptococcal vaccinationCluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional studyChitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus.Infectivity and insertional mutagenesis of endogenous retrovirus in autoimmune NZB and B/W mice.Induction of autoimmunity by pristane and other naturally occurring hydrocarbons.Effects of acute and chronic inflammation on B-cell development and differentiation.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.Infections in hemodialysis: a concise review - Part 1: bacteremia and respiratory infections.Phytol-derived novel isoprenoid immunostimulants.Synthetic adjuvants for vaccine formulations: phytol derivatives.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Queries about vaccines containing squalene.Infections, vaccines and autoimmunity.Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production.Absence of citrulline-specific autoantibodies in animal models of autoimmunity.Scientific Opinion on Mineral Oil Hydrocarbons in FoodVaccination and triploidy increase relative heart weight in farmed Atlantic salmon, Salmo salar L.Immunomodulatory Effect of Agave tequilana Evaluated on an Autoimmunity Like-SLE Model Induced in Balb/c Mice with Pristane.Characterization of a PRISTANE-induced lupus-associated model in the non-human primate cynomolgus monkey.Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation.Targeted IgA Fc receptor I (FcαRI) therapy in the early intervention and treatment of pristane-induced lupus nephritis in mice.
P2860
Q28475973-3F6AB638-C6BA-429F-9A8D-1CF89BBCF3C2Q28730881-D0F42918-1E09-4912-9937-866AFA08C1A5Q30408080-AC5BCB6B-7B1F-44E4-B086-85EA18C8453EQ34046148-E1E42A2E-B29F-448C-92C7-02EDC4658F05Q34056902-A30A464D-DE5E-4306-B68D-5BADF30FDA57Q34500175-D1F5C2EA-8B88-489F-AAE9-B1F4C5016C19Q34612240-566F7BAB-8C5B-4D3B-9F8F-5E062CD3D1C6Q34788943-041E6852-DC47-4C67-8BB6-8E3FC864F957Q34992787-B38CE1EC-4117-47A2-BC2F-81817E5373C7Q35088161-B75D5072-62EF-4F09-96F8-FCFEC21E1948Q35127314-55293F3C-80AE-4F45-A3E9-DDF3B7C80C50Q35192883-0235E3C4-CC73-4C53-8698-A8C127189B87Q35677926-5496B6BE-49FC-4FD8-AC4F-35288D14744EQ35839060-89E8DFFF-68F3-4062-9552-F413DCF0FB24Q36091161-8D1BA389-0F5E-422F-97A9-DF7E127DD3ABQ36725555-BC38C5D6-A256-40E9-BE2F-6911040C5AFFQ37351980-EFB58532-8192-45FE-B010-45BA32B8E198Q37369902-8E86A0C1-120E-453E-929F-1B6361351F60Q37706610-995E89FE-1277-405D-933B-A514F500F964Q37878862-4D65F209-9696-4650-972B-226B02445C89Q38008360-EC9CC936-B8EF-41E4-AD9B-527AB7042214Q38072067-51DF5B29-D030-4D41-9EEC-F0723B36CAF7Q38260496-5F5C4150-8A5F-4702-B68E-6F340AE665AAQ43161303-BC102F93-F99B-4C50-A1A9-886D5F157FA1Q43724066-FB907F79-D378-4EF1-82F7-4778D8D2A654Q44838313-8DB318EC-6E8F-48F2-9372-19A68BE5AB0CQ44973891-40514FB5-E911-4487-A475-B91717A0CABDQ47151832-DE89612E-D441-4B55-8011-AC07E02F7C34Q47188957-B6373CE3-93AE-402F-8544-8B52F21D0CB3Q47740044-2DF15DAF-4FB6-4ED2-99B6-2C595B4F5F33Q48338382-F703CF89-2C51-4555-9C6D-039AD27E1A06Q50865023-B4284C51-50A9-4A8A-ADDD-A2B9D16927C2Q55059074-824F9C38-15E4-4102-A62E-C4F9BCD7B25C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Induction of lupus autoantibodies by adjuvants
@ast
Induction of lupus autoantibodies by adjuvants
@en
Induction of lupus autoantibodies by adjuvants
@nl
type
label
Induction of lupus autoantibodies by adjuvants
@ast
Induction of lupus autoantibodies by adjuvants
@en
Induction of lupus autoantibodies by adjuvants
@nl
prefLabel
Induction of lupus autoantibodies by adjuvants
@ast
Induction of lupus autoantibodies by adjuvants
@en
Induction of lupus autoantibodies by adjuvants
@nl
P2093
P1476
Induction of lupus autoantibodies by adjuvants
@en
P2093
Akiei Mizutani
Dina C Nacionales
Hideo Yoshida
Jun Akaogi
Krista M Behney
Minoru Satoh
Robert J Rosenbauer
Thomas D Lorenson
Westley H Reeves
Yoshiki Kuroda
P356
10.1016/S0896-8411(03)00083-0
P407
P577
2003-08-01T00:00:00Z